Hospitalizations

• Un estudio reciente demuestra que una formulación de vacuna actualizada redujo las visitas a los departamentos de urgencias y las hospitalizaciones entre adultos sanos en aproximadamente un 50 por ciento durante la temporada pasada. • Esta mejora significativa de la eficacia representa un avance importante en el desarrollo de vacunas y en las estrategias de protección de la salud pública. • Los hallazgos contribuyen al panorama en evolución de la política de vacunas de U.S., tal como se documenta en el último informe sobre el estado de la política de vacunas de CIDRAP del 28 de abril de 2026.

• The U.S. daily COVID-19 case average increased by 13.3% over the past week, though hospitalizations continue to decline according to federal data. • About 48,000 patients are currently hospitalized with COVID-19, representing a decrease of nearly 104,000 patients over the past eight weeks, with hospital admissions down 11.7% weekly. • Alaska has the highest infection rate in the nation, followed by Montana, North Dakota, and Wyoming, while Puerto Rico, Florida, and Hawaii report the lowest rates.

• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.